Ardelyx Tops Estimates as Sales Surge
The biopharma reported strong revenue growth in the fourth quarter thanks to solid performances from both of its approved products, Ibsrela and Xphozah.
Ardelyx (NASDAQ:ARDX), a biopharmaceutical company specializing in innovative treatments for gastrointestinal and kidney diseases, released its fourth-quarter earnings report on Feb. 20. The release highlighted considerable progress in the company's commercialization of its two approved drugs, Ibsrela and Xphozah. The company reported earnings per share (EPS) of $0.02, higher than the analysts' consensus estimate of $0.01. Revenue of $116.1 million exceeded the expected $111 million.
Source: Analysts' estimates for the quarter provided by FactSet.
Ardelyx develops treatments for irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia, a condition often found in chronic kidney disease patients who are on dialysis. Its products, Ibsrela and Xphozah, cater to significant medical needs that were previously unmet, offering unique mechanisms of action.
